首页> 外文OA文献 >A Switch of G Protein-Coupled Receptor Binding Preference from Phosphoinositide 3-Kinase (PI3K)–p85 to Filamin A Negatively Controls the PI3K Pathway
【2h】

A Switch of G Protein-Coupled Receptor Binding Preference from Phosphoinositide 3-Kinase (PI3K)–p85 to Filamin A Negatively Controls the PI3K Pathway

机译:从磷酸肌醇3-激酶(PI3K)–p85到丝蛋白A的G蛋白偶联受体结合偏好的转换对PI3K通路产生负面影响。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Frequent oncogenic alterations occur in the phosphoinositide 3-kinase (PI3K) pathway, urging identification of novel negative controls. We previously reported an original mechanism for restraining PI3K activity, controlled by the somatostatin G proteincoupled receptor (GPCR) sst2 and involving a ligand-regulated interaction between sst2 with the PI3K regulatory p85 subunit. We here identify the scaffolding protein filamin A (FLNA) as a critical player regulating the dynamic of this complex. A preexisting sst2-p85 complex, which was shown to account for a significant basal PI3K activity in the absence of ligand, is disrupted upon sst2 activation. FLNA was here identified as a competitor of p85 for direct binding to two juxtaposed sites on sst2. Switching of GPCR binding preference from p85 toward FLNA is determined by changes in the tyrosine phosphorylation of p85- and FLNA-binding sites on sst2 upon activation. It results in the disruption of the sst2-p85 complex and the subsequent inhibition of PI3K. Knocking down FLNA expression, or abrogating FLNA recruitment to sst2, reversed the inhibition of PI3K and of tumor growth induced by sst2. Importantly, we report that this FLNA inhibitory control on PI3K can be generalized to another GPCR, the mu opioid receptor, thereby providing an unprecedented mechanism underlying GPCR-negative control on PI3K.
机译:磷酸肌醇3-激酶(PI3K)途径中经常发生致癌改变,敦促鉴定新的阴性对照。我们先前报道了一种抑制PI3K活性的原始机制,该机制受生长抑素G蛋白偶联受体(GPCR)sst2的控制,并且涉及sst2与PI3K调节性p85亚基之间的配体调节相互作用。我们在这里确定支架蛋白丝蛋白A(FLNA)是调节这种复合物的动态的关键参与者。先前存在的sst2-p85复合物在sst2激活后被破坏,这表明在不存在配体的情况下具有重要的基础PI3K活性。在这里,FLNA被鉴定为p85的竞争者,可直接结合到sst2上的两个并列位点。 GPCR结合偏好从p85向FLNA的转换取决于激活后sst2上p85和FLNA结合位点酪氨酸磷酸化的变化。其导致sst2-p85复合物的破坏和随后对PI3K的抑制。敲低FLNA表达或将FLNA募集废除为sst2,可逆转PI3K和sst2诱导的肿瘤生长的抑制作用。重要的是,我们报道这种对PI3K的FLNA抑制控制可以推广到另一个GPCR,即阿片类阿片受体,从而为PI3K的GPCR阴性控制提供了前所未有的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号